132 related articles for article (PubMed ID: 9842986)
1. Human liver microsomal metabolism of paclitaxel and drug interactions.
Desai PB; Duan JZ; Zhu YW; Kouzi S
Eur J Drug Metab Pharmacokinet; 1998; 23(3):417-24. PubMed ID: 9842986
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions of paclitaxel metabolism in human liver microsomes.
Bun SS; Ciccolini J; Bun H; Aubert C; Catalin J
J Chemother; 2003 Jun; 15(3):266-74. PubMed ID: 12868554
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.
Václavíková R; Horský S; Simek P; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):200-9. PubMed ID: 12920504
[TBL] [Abstract][Full Text] [Related]
4. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Kang MH; Figg WD; Ando Y; Blagosklonny MV; Liewehr D; Fojo T; Bates SE
Clin Cancer Res; 2001 Jun; 7(6):1610-7. PubMed ID: 11410497
[TBL] [Abstract][Full Text] [Related]
5. Variability in human cytochrome P450 paclitaxel metabolism.
Sonnichsen DS; Liu Q; Schuetz EG; Schuetz JD; Pappo A; Relling MV
J Pharmacol Exp Ther; 1995 Nov; 275(2):566-75. PubMed ID: 7473140
[TBL] [Abstract][Full Text] [Related]
6. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs.
Vaclavikova R; Soucek P; Svobodova L; Anzenbacher P; Simek P; Guengerich FP; Gut I
Drug Metab Dispos; 2004 Jun; 32(6):666-74. PubMed ID: 15155559
[TBL] [Abstract][Full Text] [Related]
7. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
8. Drug-interaction between paclitaxel and goshajinkigan extract and its constituents.
Nakayama A; Tsuchiya K; Xu L; Matsumoto T; Makino T
J Nat Med; 2022 Jan; 76(1):59-67. PubMed ID: 34304352
[TBL] [Abstract][Full Text] [Related]
9. The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):408-14. PubMed ID: 26551762
[TBL] [Abstract][Full Text] [Related]
10. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.
Royer I; Monsarrat B; Sonnier M; Wright M; Cresteil T
Cancer Res; 1996 Jan; 56(1):58-65. PubMed ID: 8548776
[TBL] [Abstract][Full Text] [Related]
12. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes.
Beulz-Riché D; Robert J; Riché C; Ratanasavanh D
Cancer Chemother Pharmacol; 2002 Apr; 49(4):274-80. PubMed ID: 11914905
[TBL] [Abstract][Full Text] [Related]
13. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel.
Zhang YY; Liu Y; Zhang JW; Ge GB; Wang LM; Sun J; Yang L
Xenobiotica; 2009 Apr; 39(4):283-92. PubMed ID: 19350451
[TBL] [Abstract][Full Text] [Related]
15. Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs.
Bun SS; Giacometti S; Fanciullino R; Ciccolini J; Bun H; Aubert C
Anticancer Drugs; 2005 Jul; 16(6):675-82. PubMed ID: 15930897
[TBL] [Abstract][Full Text] [Related]
16. High-Performance Liquid Chromatography Analysis of CYP2C8-Catalyzed Paclitaxel 6α-Hydroxylation.
Crespi CL; Chang TK; Waxman DJ
Methods Mol Biol; 2006; 320():103-107. PubMed ID: 27699666
[TBL] [Abstract][Full Text] [Related]
17. Reversal activity of cyclosporin A and its metabolites M1, M17 and M21 in multidrug-resistant cells.
Toffoli G; Corona G; Sorio R; Bertola A; Boiocchi M
Int J Cancer; 1997 May; 71(5):900-6. PubMed ID: 9180163
[TBL] [Abstract][Full Text] [Related]
18. Quantitative determination of paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel, in human plasma using column-switching liquid chromatography/tandem mass spectrometry.
Yamaguchi H; Fujikawa A; Ito H; Tanaka N; Furugen A; Miyamori K; Takahashi N; Ogura J; Kobayashi M; Yamada T; Mano N; Iseki K
Biomed Chromatogr; 2013 Apr; 27(4):539-44. PubMed ID: 23018973
[TBL] [Abstract][Full Text] [Related]
19. Taxane's substituents at C3' affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel.
Zhang JW; Ge GB; Liu Y; Wang LM; Liu XB; Zhang YY; Li W; He YQ; Wang ZT; Sun J; Xiao HB; Yang L
Drug Metab Dispos; 2008 Feb; 36(2):418-26. PubMed ID: 18039807
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.
Jamis-Dow CA; Klecker RW; Katki AG; Collins JM
Cancer Chemother Pharmacol; 1995; 36(2):107-14. PubMed ID: 7767945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
